摘要
目的 研究中国健康成年男性志愿者连续口服D 聚甘酯片的药动学。方法 选择经体检及实验室检查均正常的健康成年男性志愿者。 12名受试者连续口服D 聚甘酯片 10d ,每日一次 ,每次 4 0 0mg。应用免疫荧光比浊法测定给药后不同时间点血浆的部分凝血活酶时间 (aPTT) ,据随行测定的aPTT 血浆浓度标准曲线 ,计算相应的血药浓度。采用 3P97软件进行数据处理 ,分别求出首次给药和末次给药后药动学参数 ,以及达稳态时间、稳态浓度、累积比和波动系数。结果 依据aPTT结果计算D 聚甘酯血浆浓度 ,在 0 .0 5~ 10mg·L-1浓度范围内呈良好的线性关系 (r =0 .995 7) ;最低检测浓度为 0 .0 5mg·L-1,回收率在 91.4 8%~ 10 5 .6 7%之间 ,日内、日间RSD小于 13%。受试者连续口服D 聚甘酯片 ,于给药后第 7天血药浓度达到稳态 ,平均稳态血药浓度cav为 (0 .4 4 2± 0 .0 6 7)mg·L-1,达稳态后血药浓度 时间曲线下面积AUCss为 (10 .6 0 2± 1.6 0 5 )mg·h·L-1,累积比R为 1.2 6 1± 0 .0 31,波动系数FI为 1.5 5 4± 0 .0 6 1。首次与末次给药后主要药动学参数cmax分别为 (1.0 4 1± 0 .10 7)和 (1.4 0 1± 0 .12 5 )mg·L-1;t1/2 β分别为 (18.934± 1.76 0 )和 (19.977± 1.0 98)h ;tmax分别为 (1.0 39± 0 .0 96 )
OBJECTIVE: To investigate the pharmacokinetics of D-polymannuronicate after multiple-dose administration in Chinese healthy volunteers. METHODS: 11 volunteers passed physical and laboratory examinations took orally D-polymannuronicate 400 mg once daily for 10 days. The aPTT was determined by immuno-fluoresence turbidity method and the plasma concentrations of D-polymannuronicate were determined by the accompanily aPTT. The plasma concentration standard curve and pharmacokinetic parameters of the first and the last dosing were calculated by 3P97 software. RESULTS: The steady concentrations were achieved after administration for 7 days. The mean steady plasma concentration (cAv) was (0.442 ± 0.067) mg·L-1. The AUCSS, accumulation rate R and the fluctation coefficient FI were (10.602 ± 1. 605) mg·h· L-1, 1.261 ± 0.031), (1.554 ± 0.061) respectively. The main parameters after the first and the last dosing were as follow: C max (1.041 ± 0.107) and (1.401 ± 0.125) mg·L-1, t1/2β (18.934 ± 1.760) and (19.977 ± 1.098) h, tmax = (1.039 ± 0.096) and (0.969 ± 0.109) h, V/F (202.167 ± 19.187) and (160.220 ± 22.274) L, CL (33.553 ± 5.038) and (24.807 ± 3.875) L· h -1 respectively. The AUC0-∞ after the first dosing was (12.195 ± 1.912) mg∼ h-1 and the AUC0-t after the last dosing was (10.602 ± 1. 605) mg·h·L -1. CONCLUSION: The steady concentration was achieved after administration for 7 days and there was no accumulation in vivo for 10 days. No correlated adverse effects took place except aPTT elongation. Once daily administration of D-polymannuronicate was recommended.
出处
《中国药学杂志》
EI
CAS
CSCD
北大核心
2003年第8期613-616,共4页
Chinese Pharmaceutical Journal